Dr. Michael Lazar

Study reveals genetic connection to aggressive prostate cancer

An international study published in the Journal of the National Cancer Institute has identified a genetic connection to the aggressive form of prostate cancer. The study showed a threefold increase in the risk of aggressive prostate cancer for men with the genetic mutation. The frequency of the gene variants varied from 6 to 14% of the population of men with prostate cancer. Much like the association between BRCA gene mutation and the risk for breast cancer in women changed the approach to treatment/ prevention, the identification of the Kallikrein 6 gene region may change the course of prostate cancer care through a blood test developed by the Lunenfeld-Tanenbaum Research Institute. The study was led by Dr. Alexandre Zlotta, Director of Uro-Oncology at Mount Sinai Hospital, [...]

2017-12-13T13:37:20+00:00 March 21st, 2017|

Researchers target cholesterol to stop prostate cancer

Advanced prostate cancer and high blood cholesterol have long been known to be connected, but it has been a chicken-or-egg problem. Now a team led by researchers at the Duke Cancer Institute have identified a cellular process that cancer cells hijack to hoard cholesterol and fuel their growth. Identifying this process could inform the development of better ways to control cholesterol accumulation in tumors, potentially leading to improved survival for prostate cancer patients. The findings are published online this month in the journal Cancer Research. "Prostate cancer cells, as well as some other solid tumors, have been shown to contain higher cholesterol levels than normal cells," said senior author Donald McDonnell, Ph.D., chairman of the Department of Pharmacology and Cancer Biology at Duke. "All cells [...]

2017-03-01T10:01:29+00:00 March 1st, 2017|

Prostate Cancer News: Emotional distress may lead to more aggressive treatment

The anxiety many men experience after being diagnosed with prostate cancer may lead them to choose potentially unnecessary treatment options, researchers from the University at Buffalo and Roswell Park Cancer Institute report in a new study. "Emotional distress may motivate men with low-risk prostate cancer to choose more aggressive treatment, such as choosing surgery over active surveillance," said UB's Heather Orom, the lead author on the study, published in the February issue of the Journal of Urology. "It underscores what we have been pushing a long time for, which is, 'Let's make this decision as informed and supported as possible.' If distress early on is influencing treatment choice, then maybe we help men by providing clearer information about prognosis and strategies for dealing with anxiety. [...]

2017-12-13T13:37:21+00:00 February 14th, 2017|

Free HIFU Info Session Scheduled for February

Do you have prostate cancer? There is now a non-invasive treatment option. Join Dr. Michael Lazar of California HIFU for a special Prostate Cancer Treatment Information session scheduled for Thurs., Feb. 16, 2017 at 7 p.m. This free session will be held at the Friedman Event Center, 4676 Mayette Ave., Santa Rosa, CA 95405. Dr. Lazar will discuss how Sonablate HIFU can treat Prostate Cancer with lower risk of side effects such as impotence and incontinence. HIFU is radiation free - provides quick recovery - requires no chemotherapy and no surgery. Free and open to the public. Call for reservations today Jennifer Radovich 707-546-5553. Refreshments will be provided. Brought to you by HIFU Prostate Services and California HIFU.

2017-12-13T13:37:21+00:00 January 31st, 2017|

Prostate Cancer Rates Take a Nose Dive Per Latest Statistics

Dr. Michael Lazar of California HIFU, Urologist and Prostate Cancer expert reflects on the latest American Cancer Society statics The results from the American Cancer Society’s newest report on cancer rates is good news for everyone and particularly good news for prostate cancer patients: incidents of cancer is down as is the likelihood of prostate cancer patients dying from the diagnosis. According to the report the cancer death rate has dropped from its peak of 215.1 in 1991 to 161.2 in 2014 (per 100K population), the most recent year for which data was available to analyze. Overall the decline in cancer is linked with decreases in smoking and advances in early detection and treatment. The four major cancer drops are: lung (- 43% between 1990 [...]

2017-06-07T08:43:49+00:00 January 23rd, 2017|

Researchers unravel genetic codes to determine why inherited prostate cancer is so deadly

Prostate cancer researchers have discovered a key piece in the genetic puzzle of why men born with a BRCA2 mutation may develop aggressive localized cancers that resist treatment and become lethal for up to 50 per cent of patients within five years. Canadian and Australian prostate cancer researchers have discovered a key piece in the genetic puzzle of why men born with a BRCA2 mutation may develop aggressive localized cancers that resist treatment and become lethal for up to 50 per cent of patients within five years. The findings, published online in Nature Communications, show that BRCA2-associated tumours are already pre-set to be aggressive, even before treatment. This is because the genes normally involved in regulating cell growth and division are abnormal in the BRCA2-associated [...]

2017-12-13T13:37:21+00:00 January 10th, 2017|

One year following FDA approval California HIFU is Giving Prostate Cancer Patients Hope for a Healthy Future

Santa Rosa Urologist Dr. Michael Lazar celebrates California HIFU’s first anniversary with look back at October 2015 when HIFU received approval from Food and Drug Administration for use in the U.S. High-intensity focused ultrasound (HIFU) is a technology that targets cancer cells with precision in a one to four-hour procedure that has little or no side effects, provides a remarkably quick recovery rate, and gives men diagnosed with prostate cancer a less invasive option over surgery or radiation. “The oncological results for HIFU is comparable to more traditional prostate cancer treatments including radical surgery or radiation. But the side effects for HIFU patients have proven to be much less debilitating than more radical procedures,” says Dr. Lazar. “For example, if the HIFU procedure is performed [...]

2017-12-13T13:37:21+00:00 November 22nd, 2016|

Researchers Find that blood samples may help predict prostate cancer spread

Researchers have found a group of circulating tumor cells in prostate cancer patient blood samples which are linked to the spread of the disease, according to new research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool. This is the first time these cell types have been shown to be a promising marker for prostate cancer spread. In a study of around 80 samples from men with prostate cancer, scientists at the Barts Cancer Institute at Queen Mary University looked for cells that were gaining the ability to migrate and invade through the body. Samples with more of these cells were more likely to come from patients whose cancer had spread or was more aggressive. This means that, in the future, these [...]

2017-12-13T13:37:21+00:00 November 15th, 2016|

Researchers discover three novel intrinsic subtypes of prostate cancer

In the largest study of its kind to date, researchers have identified and validated three distinct molecular subtypes of prostate cancer that correlate with distant metastasis-free survival and can assist in future research to determine how patients will respond to treatment, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO). Findings represent a step toward the implementation of personalized medicine in prostate cancer care. To diagnose and determine treatment for prostate cancer, clinicians consider many factors, including a digital rectal exam, the prostate specific antigen (PSA) level in a patient's blood and prostate tumor biopsy results. Molecular subtyping of tumor cells allows oncologists to individualize care and tailor treatment based on the actual biology of each patient's [...]

2017-12-13T13:37:21+00:00 November 1st, 2016|

New trial results encourage patients to weigh long-term impact of treatment options with their doctors

(Published on ScienceDaily - September 15, 2016) In light of the findings from the Prostate Testing for Cancer and Treatment (ProtecT) trial published in the New England Journal of Medicine, the American Society for Radiation Oncology (ASTRO) would like to congratulate the authors and investigators for conceiving and completing a difficult clinical trial to randomize care for 2,664 men who volunteered to be a part of this study. Their paper emphasizes the importance of joint decision making between prostate cancer patients and their physicians when weighing treatment options for early stage disease. Findings from the ProtecT trial can help patients understand the full range of approaches to manage their disease, including the risks and benefits of active monitoring versus early treatment with radiation therapy (RT) [...]

2017-12-13T13:37:22+00:00 September 20th, 2016|